FDAsafety guidance72% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · EGFR Inhibitor
- Sub-indication
- Lung Cancer
Related signal: AstraZeneca licenses novel EGFR inhibitor Zegfrovy for lung cancer